04-02-2021 | Diabetes | News | Article
High CVD risk at type 2 diabetes diagnosis increasingly common
The proportion of people with new-onset type 2 diabetes who have high cardiovascular risk has increased consistently over time, with a particularly notable rise in the prevalence of cardiometabolic multimorbidity among young people, researchers report.
15-01-2021 | Diabetes | News | Article
SGLT2 inhibition may reduce myocardial extracellular volume
Treatment with the SGLT2 inhibitor empagliflozin is associated with a reduction in myocardial extracellular volume among individuals with type 2 diabetes and coronary artery disease, suggests an analysis of data from the EMPA-HEART CardioLink-6 trial.
Heart and stethoscope 2/© MarsBars / Getty Images / iStock, Heart and white pills/© kooshevoy / Fotolia, Heart and stethoscope/© cnythzl/Getty Images/iStock